OmniAb (NASDAQ:OABI) Sees Strong Trading Volume – Time to Buy?

Posted by Brian Himes on Oct 23rd, 2026

OmniAb, Inc. (NASDAQ:OABI – Get Free Report) saw unusually-high trading volume on Wednesday. 2,528,665 shares changed hands during mid-day trading, an increase of 194% from the previous session’s volume of 861,331 shares. The stock last traded at $4.8250 and had previously closed at $4.96.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Leerink Partners boosted their price objective on OmniAb from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Wednesday, October 7th. Weiss Ratings raised shares of OmniAb from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 20th. Finally, HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of OmniAb in a report on Monday, August 17th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $11.50.

Check Out Our Latest Analysis on OmniAb

OmniAb Trading Down 2.7%

The firm has a market capitalization of $673.23 million, a PE ratio of -12.92 and a beta of 0.60. The stock has a 50 day simple moving average of $4.54 and a 200 day simple moving average of $2.98.

OmniAb (NASDAQ:OABI – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.07. OmniAb had a negative net margin of 115.12% and a negative return on equity of 16.59%. The business had revenue of $13.41 million for the quarter, compared to analyst estimates of $4.69 million. As a group, equities analysts anticipate that OmniAb, Inc. will post -0.35 earnings per share for the current year.

Institutional Trading of OmniAb

Large investors have recently bought and sold shares of the company. Legal & General Group Plc bought a new position in OmniAb in the second quarter worth $28,000. Canada Pension Plan Investment Board bought a new stake in shares of OmniAb in the 2nd quarter worth approximately $37,000. Two Sigma Securities LLC purchased a new stake in shares of OmniAb in the 2nd quarter worth approximately $39,000. State of Wyoming increased its holdings in shares of OmniAb by 101.7% during the first quarter. State of Wyoming now owns 24,694 shares of the company’s stock valued at $39,000 after acquiring an additional 12,451 shares in the last quarter. Finally, The Manufacturers Life Insurance Company bought a new position in OmniAb in the 2nd quarter worth about $61,000. 72.08% of the stock is owned by institutional investors.

OmniAb Company Profile

(Get Free Report)

OmniAb, Inc is a biotechnology company that develops and licenses antibody discovery technologies for use in drug research and development. Its platform is designed to help biopharmaceutical companies generate fully human and species-diverse antibodies that can be evaluated as potential treatments for a range of diseases.

The company’s technology portfolio includes genetically engineered animal platforms, such as OmniRat, OmniMouse and OmniChicken, which are used to produce antibody candidates against challenging biological targets.